Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company’s cl... Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company’s clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.01 | 7.68645357686 | 13.14 | 14.46 | 13.02 | 998249 | 13.84656715 | CS |
| 4 | -0.17 | -1.18715083799 | 14.32 | 14.87 | 12.985 | 816799 | 14.00582633 | CS |
| 12 | 0.52 | 3.81511371974 | 13.63 | 16.595 | 12.985 | 953779 | 14.41384052 | CS |
| 26 | -0.03 | -0.211565585331 | 14.18 | 16.595 | 12.12 | 1167684 | 14.07960647 | CS |
| 52 | -8.8 | -38.3442265795 | 22.95 | 35.34 | 12.12 | 1172554 | 18.73013798 | CS |
| 156 | 1.63 | 13.0191693291 | 12.52 | 71.71 | 5.65 | 818093 | 30.42385641 | CS |
| 260 | -2.9053 | -17.0345874889 | 17.0553 | 71.71 | 5.65 | 534946 | 29.4728559 | CS |
ed3/6me
10月前
Alan Brown
2年前
Alan Brown
2年前
Alan Brown
2年前
stock _Hunter
2年前
homeboy
2年前
Invest-in-America
2年前
Invest-in-America
2年前
Awl416
2年前
Invest-in-America
2年前
isisevan
21年前
Wise Investment
24年前
pontang
24年前
Wise Investment
24年前
Wise Investment
24年前
Wise Investment
24年前
Wise Investment
24年前
Wise Investment
24年前
Wise Investment
24年前
Wise Investment
24年前
Bev9999
24年前
Wise Investment
24年前
Bev9999
24年前
Wise Investment
24年前
Bev9999
24年前
Bev9999
24年前
Wise Investment
24年前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。